ClinicalTrials.gg
Not yet recruitingNCT07950657TeGRASP-VNSUpdated Nov 20, 2026

taVNS and Rehabilitation After Grasp Reconstruction in Tetraplegia: A Randomized Feasibility Study

An interventional study of Active vagus nerve stimulation and Placebo vagus nerve stimulation in Tetraplegia/Tetraparesis, sponsored by Sahlgrenska University Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Sahlgrenska University Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether transcutaneous auricular vagus nerve stimulation (taVNS) is feasible, safe and tolerable when combined with standard rehabilitation after surgery to restore grasp in adults with tetraplegia caused by spinal cord injury. taVNS delivers gentle electrical stimulation through an electrode placed on the outer ear.

The main questions it aims to answer are:

  • Can participants follow the treatment schedule and complete the study assessments?
  • Is the treatment well tolerated, and what side effects or medical problems occur?
  • Are there preliminary differences in grasp function, tendon movement and daily activities between participants receiving active treatment and those receiving sham treatment?
  • Does active treatment affect blood markers of inflammation and scar tissue formation? Researchers will compare active taVNS with sham treatment delivered using an identical device and a specially designed electrode that provides subtle sensory feedback without electrical stimulation. Both groups will receive the same standard postoperative rehabilitation. Approximately 40 adults undergoing surgical grasp reconstruction at the Center for Advanced Reconstruction of Extremities (CARE), Sahlgrenska University Hospital/Mölndal, Sweden, will be randomly assigned to the two groups in equal numbers. Participants, treating therapists and outcome assessors will not know which treatment participants receive.

Participants will:

  • Use the assigned device with an electrode on the left outer ear for 60 minutes daily, starting during the week of surgery and continuing for three months.
  • Receive training, together with a caregiver where needed, to use the device at home.
  • Return for a five-day inpatient rehabilitation stay three weeks after surgery, during which treatment will be supervised.
  • Complete assessments before surgery and at three weeks, 12 weeks, six months and 12 months after surgery.
  • Complete tests of grasp function, grip and pinch strength, hand opening and movement, together with questionnaires about daily activities, independence, bowel function, mood and quality of life.
  • Undergo ultrasound examinations to assess tendon movement and scar tissue around the tendons.
  • Provide blood samples before and at several time points after surgery to investigate inflammation and tissue healing.
  • Record each treatment session in a diary and report side effects or difficulties using the device.

Approximately 10-15 participants will also be invited to an interview about their experiences of treatment and rehabilitation around three months after surgery.

This feasibility study will help researchers plan a larger trial to determine whether adding taVNS to rehabilitation improves recovery after surgical grasp reconstruction.

Read the detailed description

Cervical spinal cord injury (SCI) frequently results in tetraplegia and severe impairment of hand function. Reconstructive surgery using tendon and muscle transfers can restore active grasp function and improve independence. However, postoperative scar formation and peritendinous adhesions may restrict tendon gliding and compromise functional recovery.

Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive neuromodulation technique with potential anti-inflammatory effects mediated through the cholinergic anti-inflammatory pathway. These effects may influence postoperative inflammation and tissue remodeling. However, the feasibility and potential clinical benefits of taVNS following reconstructive hand surgery in individuals with tetraplegia have not previously been systematically investigated.

This single-center, randomized, triple-blind, sham-controlled feasibility trial will enroll 40 adults with tetraplegia undergoing surgical reconstruction of grasp function at Sahlgrenska University Hospital, Sweden. Participants will be consecutively recruited and randomly allocated in a 1:1 ratio to active taVNS or sham stimulation, both combined with standard postoperative rehabilitation. Randomization will be stratified according to the International Classification for Surgery of the Hand in Tetraplegia (ICSHT).

Stimulation will be initiated during the week of surgery and administered for 60 minutes daily over a three-month period, primarily in the home setting. Active stimulation will be delivered to the left tragus using a Nurosym device at 25 Hz and a pulse width of 250 μs. The sham group will use an identical device with a sham electrode that does not deliver electrical stimulation.

The primary objective is to evaluate the feasibility, safety, tolerability, and acceptability of integrating taVNS into postoperative rehabilitation. Feasibility will be assessed through recruitment, adherence, retention, and treatment-related safety outcomes.

Preliminary clinical effects will be explored through assessments of grasp function, muscle strength, range of motion, tendon gliding, independence, activity performance, and quality of life. Blood samples collected during the early postoperative period will be used to investigate inflammatory and tissue-remodeling responses. A qualitative substudy will explore participants' experiences of using taVNS during postoperative rehabilitation.

Clinical assessments will be conducted before surgery and at approximately 3 weeks, 3 months, 6 months, and 12 months postoperatively. Findings will inform the design and implementation of a future definitive randomized controlled trial.

02

Conditions studied

  • Tetraplegia/Tetraparesis

Keywords

  • Tetraplegia
  • Spinal Cord Injury
  • Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
  • Grasp Reconstruction
  • Tendon Transfer Surgery
  • Postoperative Rehabilitation
  • Feasibility Study
  • Hand Function
  • Inflammation
  • Tendon Adhesions
  • Randomized Controlled Trial
03

In context

Quadriplegia

224 studies on the registry are indexed under Quadriplegia; 77 are open to participants now.

This study's planned enrollment of 40 is above the median of 15 across 195 interventional studies indexed under Quadriplegia.

Browse Quadriplegia studies →

Lead sponsor

Sahlgrenska University Hospital is the lead sponsor of 264 studies on the registry; 69 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥18 years) with tetraplegia due to SCI
  • Planned reconstructive surgery of the upper limb to restore grip function
  • Medically stable and considered suitable for surgery and postoperative rehabilitation
  • Ability to understand the study information and provide
  • Ability to participate in postoperative rehabilitation and follow-ups according to the study protocol

Exclusion criteria

Exclusion Criteria:

  • Implanted pacemaker, ICD, neurostimulator, or previous surgery on the vagus nerve

    • to electrical stimulation or electrode placement at the tragus
    • cardiac arrhythmia, symptomatic bradycardia, or myocardial infarction within the past five years
    • Severe autonomic instability (e.g., recurrent autonomic dysreflexia requiring acute treatment, syncope due to orthostatic hypotension, or unstable blood pressure)
    • Trigeminal neuralgia within the past year
    • Active systemic or inflammatory disease or ongoing therapy
    • Progressive neuromuscular disease affecting upper limb function
    • Severe psychiatric illness or substance use disorder affecting study participation
    • Any other medical condition that, in the investigator's judgment, may affect the subject's ability to participate safely in the study or interfere with the interpretation of the study results.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Active vagus nerve stimulation paired with standard postoperative rehabilitation

    Stimulation will be initiated during the week of surgery and administered for 60 minutes daily over a three-month period, primarily in the home setting. Active stimulation will be delivered to the left tragus using a Nurosym device at 25 Hz and a pulse width of 250 μs.

    Device: Active vagus nerve stimulation

  • Active comparator
    Placebo vagus nerve stimulation paired with standard postoperative rehabilitation

    The sham group will use an identical device with a sham electrode that does not deliver electrical stimulation.

    Other: Placebo vagus nerve stimulation

Interventions

  • DeviceActive vagus nerve stimulation

    Active taVNS will be delivered using the Nurosym device (Parasym Health Ltd., UK), with the electrode positioned on the left tragus. Stimulation will be administered at 25 Hz and 250 μs, with intensity individually adjusted to a comfortable sensory level and then reduced by one increment. Treatment will be administered for 60 minutes daily over three months, alongside standard postoperative rehabilitation.

    Also known as: Auricular Vagus Nerve Stimulation (aVNS), Transcutaneous Vagus Nerve Stimulation (tVNS)

  • OtherPlacebo vagus nerve stimulation

    Sham taVNS will be delivered using an identical Nurosym device equipped with a sham electrode positioned on the left tragus, providing subtle sensory feedback without electrical stimulation. Treatment will follow the same schedule as active taVNS (60 minutes daily for three months), alongside standard postoperative rehabilitation.

06

What researchers measure

Primary outcomes

  1. Change from baseline in grip function as assessed by Grasp and Release Test (GRT)

    The primary clinical outcome measure is grip function evaluated using the Grasp and Release Test (GRT). This test assesses the ability to pick up, move, and release six objects of varying size, weight, and surface texture using either a power grasp (cylindrical grip) or a pinch grasp (key grip). The GRT was developed to evaluate grip function following reconstructive surgery in individuals with tetraplegia. The instrument has demonstrated good test-retest reliability and is capable of detecting changes in hand function following tendon transfer procedures.

    Time frame: From enrollment to the last follow-up at 12 months

  2. Recruitment rate

    Recruitment rate will be evaluated by recording the number of screened, included, and randomized participants, as well as the proportion of participants who complete the study protocol. Reasons for non-inclusion and declined participation will be documented whenever possible.

    Time frame: From enrollment to the last follow-up at 12 months.

  3. Adherence to the intervention

    Adherence to the intervention will be evaluated by having participants, with support from assistants or relatives if needed, document all treatment sessions in a treatment diary.

    Time frame: From the first treatment session to the end of treatment at 12 weeks.

  4. Dropouts and study discontinuations

    Dropouts and study discontinuations will be systematically recorded, and reasons for withdrawal will be documented. The intention-to-treat principle will be applied in the data analysis.

    Time frame: From enrollment to the last follow-up at 12 months.

  5. The quality of blinding

    The quality of blinding will be evaluated by asking participants, after assessing the primary outcome measure, about their perceived group allocation and the degree of certainty regarding this assumption. Participants will select one of five predefined response options: certain they received taVNS, believed they received taVNS, certain they received sham stimulation, believed they received sham stimulation, or uncertain of their group allocation.

    Time frame: From the first treatment session to the end of treatment at 12 weeks.

  6. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Safety and Tolerability will be evaluated through documentation of treatment-related discomfort, discontinuation of the intervention, and the occurrence of adverse events (AE) and serious adverse events (SAE).

    Time frame: From the start of treatmetnt to the last follow-up at 12 months.

Secondary outcomes

  1. Change from baseline in grip strength as assessed by JAMAR hydraulic hand dynamometer

    Grip strength will be measured using a JAMAR hydraulic hand dynamometer, which has demonstrated good validity and reliability. The participant is instructed to sit with the elbow flexed at 90 degrees, then grips as forcefully as possible using a cylindrical grip for 3-5 seconds. Three measurements will be performed, and the highest value will be used for analysis

    Time frame: From enrollment to the last follow-up at 12 months

  2. Change from baseline in pinch grep strenght as assessed by Pinch Gauge

    Pinch grip strength (key pinch) will be measured using a Pinch Gauge. Measurement of pinch strength is a reliable tool in many musculoskeletal, systemic, and neurological conditions, and has proven useful in individuals with tetraplegia. Participants sit with the arm alongside the body and the elbow flexed at 90 degrees. The maximum value of three attempts will be used for analysis.

    Time frame: From enrollment to the last follow-up at 12 months

  3. Change in the ability to grasp and release objects as assessed by he Cylinder Test

    The Cylinder Test assesses the patient's ability to grasp and release cylinders of varying diameters ranging from 20 to 150 mm. Preliminary evaluation supports the face validity, manual clarity, feasibility, and perceived clinical relevance of the CyT for assessing functional hand opening in neurological upper limb rehabilitation

    Time frame: From enrollment to the last follow-up at 12 months

  4. Change from baseline in active and passive range of motion as assessed by a goniometer

    The universal goniometer has shown good to excellent reliability in previous studies. To ensure high measurement reliability, all measurements will be performed by the same therapist, using a standardized method and the same measurement instrument.

    Time frame: From enrollment to the last follow-up at 12 months

  5. Change from baseline in active and passive range of finger motion (tendon gliding) as assessed by Total Active Motion (TAM) and Total Passive Motion (TPM)

    To obtain a functional measure of tendon gliding, Total Active Motion (TAM) and Total Passive Motion (TPM) will be used. TAM is calculated according to the standardized method developed by the American Society for Surgery of the Hand (ASSH). TAM is defined as the sum of active motion in the metacarpophalangeal (≈85°), proximal interphalangeal (≈110°), and distal interphalangeal joints (≈65°) minus any extension deficit in the same joints. To express active motion as a percentage, the measured TAM value is divided by 260 and multiplied by 100. The same principle is applied when calculating TPM. Results are classified as follows: 100% = normal; 75-99% = good; 50-74% = fair; \<50% = poor. A large TPM combined with a low TAM strongly suggests tendon adhesions and impaired tendon gliding. Similar values for TAM and TPM indicate joint stiffness rather than adhesions. The difference between TAM and TPM is therefore used clinically to identify tendon adhesions.

    Time frame: From enrollment to the last follow-up at 12 months

  6. Change from baseline in activity performance as assessed by the Canadian Occupational Performance Measure (COPM)

    COPM is an individualized and client-centered instrument designed to detect changes over time in an individual's self-perceived performance in daily activities. COPM has demonstrated good test-retest reliability and validity across multiple populations, treatment settings, and countries, and is sensitive to change in individuals with SCI.

    Time frame: From enrollment to the last follow-up at 12 months

  7. Change from baseline in activity performance as assessed by the Tetraplegic Upper Limb Activity Questionnaire (TUAQ)

    TUAQ assesses performance and satisfaction in individuals with tetraplegia. Each scale includes the same ten questions with a five-point response scale. Scores are summed into a raw score for each scale and then converted into interval scales using a conversion table. TUAQ is intended for both clinical assessment and as an outcome measure following upper limb interventions in tetraplegia and has demonstrated good internal validity and reliability.

    Time frame: From enrollment to the last follow-up at 12 months

  8. Dynamic ultrasound and differential motion testing (tendon excursion)

    Adhesion formation and tendon gliding will be evaluated using dynamic ultrasound and differential motion testing (tendon excursion) three months postoperatively. Previous studies have shown ultrasound to be useful for identifying adhesions. The examination is performed using a high-frequency probe in longitudinal and transverse views while the patient performs finger movements. The assessment evaluates how freely and smoothly the tendon glides, any movement delay, and signs of adhesions such as restricted tendon movement or surrounding tissue moving together with the tendon.

    Time frame: From enrollment to the last follow-up at 12 months

Other outcomes

  1. Change from baseline in health-related quality of life as assessed by EuroQol-5D (EQ-5D)

    Respondents rate their health across five specific dimensions, with each dimension evaluated on a 5-level severity scale (from 1 = no problems to 5 = extreme problems / unable to perform): Mobility: Walking and moving about. Self-Care: Washing or dressing oneself. Usual Activities: Work, study, housework, family, or leisure activities. Pain / Discomfort: Physical aches or suffering. Anxiety / Depression: Emotional state, feeling worried, sad, or unhappy. Combining the score (1 to 5) from each of the five dimensions creates a unique 5-digit health state profile. The EQ VAS (Visual Analogue Scale) is a vertical, thermometer-style scale (ranging from 0 to 100) where patients mark their overall health today. 0 represents "the worst health you can imagine," and 100 represents "the best health you can imagine".

    Time frame: From enrollment to the last follow-up at 12 months

  2. Change from baseline in mental health as assesseb by Patient Health Questionnaire (PHQ-9)

    PHQ-9 is a validated short self-report scale used for screening major depression and assessing the current level of depressive symptoms. Patients report how often they have experienced nine different problems over the past two weeks, such as feeling down or hopeless, sleep disturbances, or difficulty concentrating. A tenth item assesses functional impairment, indicating how these symptoms affect work, household responsibilities, and social interactions. As a severity measure, the PHQ-9 score can range from 0 to 27, since each of the 9 items can be scored from 0 (not at all) to 3 (nearly every day).

    Time frame: From enrollment to the last follow-up at 12 months

  3. Change from baseline in bowel function as assessed by the Neurogenic Bowel Dysfunction (NBD) score

    The Neurogenic Bowel Dysfunction (NBD) Score is a 10-item, symptom-based questionnaire designed to evaluate bowel management and symptom severity-originally developed for patients with spinal cord injuries. The validated NBD questionnaire consists of 10 questions covering bowel emptying time, constipation, fecal incontinence, uncontrollable gas, and perianal skin problems. The total score indicates the severity of bowel dysfunction. * Total Score Range: 0 to 47 points (each response is weighted based on its impact on quality of life). * 0-6 points: Very minor bowel dysfunction * 7-9 points: Minor bowel dysfunction * 10-13 points: Moderate bowel dysfunction * 14+ points: Severe bowel dysfunction

    Time frame: From enrollment to the last follow-up at 12 months

  4. Change in functional ability and degree of independence as assessed by Spinal Cord Independence Measure IV

    SCIM IV is a comprehensive clinical assessment tool designed to measure independence in individuals with SCI when performing basic activities of daily living (ADL). SCIM IV evaluates 19 items across three main domains, yielding a total score from 0 to 100: * Self-Care (Items 1-4, Score: 0-20): Evaluates daily activities such as feeding, bathing, and dressing. * Respiration and Sphincter Management (Items 5-8, Score: 0-40): Evaluates respiration, bladder management, bowel management, and use of the toilet. * Mobility (Items 9-14 / 9 items total, Score: 0-40): Divided into two sub-areas: * Room and toilet mobility: Bed mobility, pressure sore prevention actions, and bed-to-wheelchair / wheelchair-to-toilet-tub transfers. * Indoors and outdoors mobility: Short, moderate, and long-distance mobility, stair management, and car-to-wheelchair transfers

    Time frame: From enrollment to the last follow-up at 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2031, 61 months later.

Of 77 non-industry interventional studies with no phase under Quadriplegia, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 309. This study's planned 61 months is close to that.

Counting every sponsor, half of 97 studies reached it within 41 months; a quarter within 16 and three quarters within 309.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 20, 2026
StartEst.
Nov 2026
Primary completionEst.
Dec 2031
CompletionEst.
Dec 2031
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950657
Collaborators
Gothia Forum - Center for Clinical Trial
Responsible party
Lina Bunketorp Käll (Associate Professor, Physiotherapist, Sahlgrenska University Hospital) — Principal investigator
First posted
Nov 20, 2026
Start date
Nov 2026 (estimated)
Primary completion
Dec 2031 (estimated)
Completion
Dec 2031 (estimated)
Last update
Nov 20, 2026

Study contacts

Lina Bunketorp Käll, PhD
Contact
lina.bunketorp@gu.se
+46 709723101

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion